SCHEMBL5607930

SCHEMBL5607930

O=C=NC12CC3CC(CC(O)(C3)C1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.42
HSD11B1 P28845 5/20 0.40
ALDH1A1 P00352 2/20 0.34
DPP4 P27487 5/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
DYRK3 O43781 1/20 0.32
CSNK1E P49674 1/20 0.32
CLK1 P49759 1/20 0.32
CLK3 P49761 1/20 0.32
GSK3B P49841 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
DYRK2 Q92630 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
DYRK4 Q9NR20 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL540055 0.86
SCHEMBL5607574 0.82 HSD11B1 (0.30) HSD11B1
SCHEMBL9186548 0.80
SCHEMBL14847323 0.78 PKM (0.47) PKMHSD11B1ALDH1A1DPP4NPC1
SCHEMBL31226224 0.77 DYRK3 (0.32) DPP4DYRK3CSNK1ECLK1CLK3
SCHEMBL31226196 0.77 THRB (0.39)
SCHEMBL6229807 0.77 PKM (0.42) PKM
SCHEMBL31226298 0.77 TSHR (0.38)
SCHEMBL75776 0.77 SIGMAR1 (0.33) HSD11B1ALDH1A1
SCHEMBL20733439 0.77 SIGMAR1 (0.33) HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092039-A1 DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE UNIV BARCELONA (ES) 2026-04-02 US disclosed
EP-4676916-A1 DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Universitat De Barcelona (ES) 2026-01-14 EP disclosed
WO-2024184305-A1 DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE UNIVERSITAT DE BARCELONA (ES) 2024-09-12 WO disclosed
US-RE39744-E1 Adamantane derivatives and process for producing them DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2007-07-24 US disclosed
US-6392104-B1 CHEMICAL INTERMEDIATES FOR DRUGS, AGRICULTURE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2002-05-21 US disclosed
EP-0927711-A1 ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM Daicel Chemical Industries, Ltd. (JP) 1999-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092039-A1 DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE2, BACE1, GLS2 PKM 2889/4885HSD11B1 963/4885ALDH1A1 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.